ClinicalTrials.gg
CompletedNCT01406431Updated Jan 3, 2013

Pharmacokinetic Study of Livalo® Fixed Combination Drug in Healthy Subjects

A Phase 1 interventional study of Pitavastatin, Valsartan and Livalo® fixed combination drug in Hyperlipidemia and Hypertension, sponsored by JW Pharmaceutical. Completed at 1 site in Korea, Republic of. Open to male participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-01-03.

Sponsored by JW Pharmaceutical · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
20 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 89 studies in Hyperlipidemias with a site in Korea, Republic of — 3 open to participants now, 5 under way, 2 of them phase 3. Hyperlipidemias · Korea, Republic of.

Enrollment
61st of 85
48 · median 80
Started
2011
with 6 others
Phase 1
39 of 89
2 open now
Registered
10th of 89
by date

Among the 89 studies in Hyperlipidemias with a site in Korea, Republic of, this one is the 61st largest by enrollment of the 85 interventional ones that give a count, is one of 7 that started in 2011, is one of 39 in phase 1, and was the 10th registered.

Hyperlipidemias

862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.

Browse Hyperlipidemias studies →

Open to participants now

3 of the 89 studies in Hyperlipidemias with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.

This study: 20 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies in Hyperlipidemias with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The purpose of this study is to compare pharmacokinetics between Pitavastatin and Valsartan co-administration and Livalo fixed combination drug in healthy male subjects.

03

Conditions studied

  • Hyperlipidemia
  • Hypertension

Keywords

  • pitavastatin
  • Livalo
04

Who can participate

Ages eligible
20 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male volunteers
  • Age 20-55 years at the time of Screening
  • 19-26 kg/m2 at the time of Screening

Exclusion criteria

Exclusion Criteria:

  • Received other drug within 90 days prior to the first dose of study drug
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Active comparator
    Pitavastatin + Valsartan

    Intervention: Drug: Pitavastatin, Valsartan

    Drug: Pitavastatin, Valsartan

  • Experimental
    Livalo fixed combination drug

    Intervention: Drug: Livalo® fixed combination drug

    Drug: Livalo® fixed combination drug

Interventions

  • DrugPitavastatin, Valsartan

    Drug pages: Pitavastatin · Valsartan

    Pitavastatin 4mg(2 tablets), Valsartan 160mg(1 tablet)

    Also known as: Livalo, Diovan

  • DrugLivalo® fixed combination drug

    Drug pages: Pitavastatin · Valsartan

    Livalo® fixed combination drug(1 tablet)

    Also known as: Livalo, Diovan

06

What researchers measure

Primary outcomes

  1. Cmax of study drugs after single oral administration

    Time frame: 0-48hrs

  2. AUClast of study drugs after single oral administration

    Time frame: 0-48hrs

Secondary outcomes

  1. AUCinf, Tmax and t1/2β of study drugs after single oral administration

    Time frame: 0-48hrs

07

Study locations

1 site
  • Asan Medical Center
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2011, a primary completion of Aug 2011 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2011
First posted
Aug 1, 2011
Start
Aug 2011
Primary completionActual
Aug 2011
CompletionActual
Oct 2012
Last update
Jan 3, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 3, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01406431
Lead sponsor
JW Pharmaceutical
Responsible party
Sponsor
First posted
Aug 1, 2011
Start date
Aug 2011
Primary completion
Aug 2011
Completion
Oct 2012
Last update
Jan 3, 2013

Study contacts

Kyun Seop Bae, MD
principal investigator · Asan Medical Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pitavastatin · Valsartan

Start the discussion